| 言語 |
英語
|
| 著者 |
Furukawa , Toshi A.
Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Kato , Tadashi
Aratama Kokorono Clinic, Nagoya, Japan
Shinagawa, Yoshihiro
Shiki Clinic, Nagoya, Japan
Miki, Kazuhira
Miki Mental Clinic, Yokohama, Japan
Fujita, Hirokazu
Center to Promote Creativity in Medical Education, Kochi Medical School, Kochi University, Nankoku, Japan
Tsujino, Naohisa
Department of Neuropsychiatry, Toho University School of Medicine, Tokyo, Japan
Kondo, Masaki
Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Yamada, Mitsuhiko
Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Tokyo, Japan
|
| 主題 | Major depression; pharmacotherapy; prediction model; remission
|
| 掲載誌名 |
PSYCHOLOGICAL MEDICINE
|
| 巻 | 49
|
| 号 | 14
|
| 開始ページ | 2405
|
| 終了ページ | 2413
|
| ISSN | 0033-2917
|
| ISSN（Online） | 1469-8978
|
| 発行日 | 2019-10
|
| DOI | |
| PubMed ID | |
| 出版者 | CAMBRIDGE UNIV PRESS
|
| 資料タイプ |
学術雑誌論文
|
| 部局 |
医学部
|
| 備考 | The study was funded by the Ministry of Health, Labor and Welfare, Japan (H-22-Seishin-Ippan-008) from April 2010 through March 2012 to TAF (http://www.mhlw.go.jp/english/), and thereafter by the Japan Foundation for Neuroscience and Mental Health (JFNMH) to TAF (http://www.jfnm.or.jp/). The JFNMH received donations from Asahi Kasei, Eli Lilly, GSK, Janssen, MSD, Meiji, Mochida, Otsuka, Pfizer, Shionogi, Taisho, and Mitsubishi-Tanabe. The study is partly supported by Japan Agency for Medical Research and Development (18dk0307072) and the Ministry of Health, Labour and Welfare (H29-ICT-Ippan-010). The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.
|
